Clinical Trial Update: A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

View source ↗

Summary

Clinical trial evaluating the combination of Yervoy (ipilimumab) and Opdivo (nivolumab) in unresectable advanced or recurrent malignant pleural mesothelioma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Mesothelioma, Malignant | Status: COMPLETED